Jim Shen’s Post

🌟 The Future of Hybrid Healthcare: Insights from Zealic CEO Chuck Piccirillo 🌟 In our latest episode of BioTalk Unzipped, Dr. Chad Briscoe and I had the pleasure of continuing our deep dive with Chuck Piccirillo, CEO of Zealic Health. We explored some of the most pressing and exciting trends in healthcare today: 🔹 Patient Journey: The unique challenges of crafting a digital and personal adaptive health journey.   🔹 Hybrid Healthcare Solutions: Why flexibility is key and how hybrid models are shaping the future.   🔹 Virtual Health in Europe: The rise of virtual health and its potential to transform patient care.   🔹 Ion Channels: Discover why these microscopic tunnels are a goldmine for new medicines.   🔹 Drug Development: Navigating the financial side of bringing new treatments to market.   🔹 Leadership in Life Sciences: The value of incremental progress, in-person interactions, and the lessons learned along the way.   🔹 Entrepreneurial Advice: Chuck shares invaluable tips for those navigating the life sciences sector. From pragmatic innovation to the importance of persistence, this episode is packed with insights for anyone interested in the future of healthcare and life sciences. 🎧 Watch now: https://lnkd.in/gtR3Hm5v Also on Apple, Spotify, Amazon, et al. #DigitalHealth #HybridHealthcare #Pharmaceutical #Biotech #Science #CEO

Essential insights on hybrid healthcare and leadership. Tune in!

🔬Life Sciences and MedTech companies face a critical challenge: understanding the real-world impact of therapeutics on patients after market entry. 💡 Lynx.MD is bridging the gap between healthcare partners and Life Sciences/MedTech innovators to bring real-world longitudinal data that delivers the insights you need now to understand patient outcomes. 📊🤝 Ready to explore the future of healthcare? Swipe through our infographic to preview the data assets we bring to innovation. 🚀 👉 Contact our team on LinkedIn today, Collin Labar, Robert Eisdorfer, MD, @Jody Bare. https://lynx.md/ #RealWorldData #LifeSciences #MedTech #HealthcareInnovation #PatientOutcomes #LynxMD

🔬Life Sciences and MedTech companies face a critical challenge: understanding the real-world impact of therapeutics on patients after market entry. 💡 @Lynx.MD bridges the gap between healthcare partners and Life Sciences/MedTech innovators to bring real-world longitudinal data that delivers the insights you need now to understand patient outcomes. 📊🤝 Ready to explore the future of healthcare? Swipe through our infographic to preview the data assets we bring to innovation. 🚀 👉 Contact our team on LinkedIn today, Collin Labar, Robert Eisdorfer, MD, Jody Bare. https://lynx.md/ hashtag #RealWorldData #LifeSciences #MedTech #HealthcareInnovation #PatientOutcomes

AI is like marmite for companies right now - love it 👍 or hate (fear) 😨 it, there is no escaping the buzz. Excited to be part of this panel at Pharma Integrates on 12th November in London, highlighting the opportunties and challenges Life Science companies face to keep pace in this new digital transformation race. https://lnkd.in/ejw6Q5DB #AI #lifesciences #digitaltransformation #datascience

𝗙𝗮𝘀𝘁 𝗙𝗮𝗰𝘁𝘀: 𝗗𝗿𝗶𝘃𝗶𝗻𝗴 𝗗𝗼𝘄𝗻 𝗖𝗼𝘀𝘁𝘀 𝗮𝗻𝗱 𝗗𝗲𝗺𝗼𝗰𝗿𝗮𝘁𝗶𝘇𝗶𝗻𝗴 𝗔𝗰𝗰𝗲𝘀𝘀 𝗶𝗻 𝗔𝗱𝘃𝗮𝗻𝗰𝗲𝗱 𝗧𝗵𝗲𝗿𝗮𝗽𝗶𝗲𝘀 As #advancedtherapies evolve, adaptable and scalable platform solutions become essential for reducing costs 𝘢𝘯𝘥 broadening patient access. Our thought leadership piece reveals key learnings to enhance the development and manufacturing of advanced therapies. In a concise 10-minute video, SK pharmteco specialists delve into innovative strategies and the transformative potential of platform approaches, advancing therapies from concept to clinical application. Watch the video: https://lnkd.in/g3MKKtru Prefer reading? Our poster presentation “Accelerate Time to Clinic for Advanced Therapies with a Platform Approach” offers a thorough overview. Download the poster: https://lnkd.in/gHBg957d Have questions? Our experts are ready to help! Ask here: https://lnkd.in/egVykeW7 John Lee Dana Cipriano, M.S. Cedrick R. #cellandgenetherapy #CDMO

Less than 4 weeks to go until our LSX USA Congress takes place in Boston (11th-12th Sept)! Next panel we'd like to highlight is.. 📣 The Convergence of Biopharma, Medtech & Healthtech – What Does This Mean for The Future of Healthcare Delivery? Join our panel of experts as they discuss: 📌Investor perspective- building a thriving ecosystem that combines startups from all three verticals 📌Going beyond ‘AI in drug discovery’ and bridging the gap between Healthtech & Biopharma 📌Discussing how the integration of digital and medical technologies is enhancing diagnostics and monitoring 📌Data – How is the industry leveraging all the patient data whilst addressing privacy concerns? 📌Real-world examples of personalized care facilitated by this convergence 🎙 Hear from: 🎤Moderator: Oliver Barnes, US Pharma & Biotech Correspondent, Financial Times Christopher Leggett, Head of Market Transformation, Vertex Pharmaceuticals Paul Geevarghese, Co-Founder & COO, 9amHealth Jim Parshall, Executive Director, Delivery Device R&D, Eli Lilly and Company Naomi Fried, Ph.D. Fried, CEO & Founder, PharmStars Jeff Chu, Managing Partner, Features Capital Find out more: https://bit.ly/4eEbT9j #LSXUSA #DigitalHealth #Medtech #Biotech

The intersection and overlap between BioTech, MedTech, and HealthTech has never been greater. Looking forward to sharing some thoughts and insights around this at #LSXUSA. Hope to see you there. #MedTech #Innovation #UnlockMedTech #AccelerateFutureOfHealthcare

Title: The High Cost of Missed Marks: Why a Flawed Launch Can Cripple Innovation and Patient Access A recent McKinsey & Company Report underscores a concerning trend: two-thirds of new biotech launches fall short of initial sales expectations, posing not only financial setbacks but also impeding scientific advancement and patient access to transformative therapies. These failures often stem from a narrow focus on a drug's scientific merits, neglecting critical market dynamics, payer considerations, and physician adoption rates. At eMIA, we advocate for a comprehensive launch strategy that goes beyond the molecule itself. By analyzing the competitive landscape, understanding evolving physician and healthcare system needs, and anticipating payer challenges, we empower companies to develop strategies that anticipate hurdles, maximize market penetration, and fulfill the promise of new therapies. The repercussions of launch failures extend beyond financial losses, delaying patient access to life-saving treatments and deterring investment in vital research areas, slowing scientific progress. We believe that every launch is an opportunity to positively impact patient lives. By bridging the gap between scientific innovation and market realities, we enable biotech leaders to navigate the launch process effectively, ensuring successful market entry for new therapies and translating breakthroughs into tangible patient benefits. With the stakes high, leaving a successful launch to chance is not an option. Read the full article @ https://lnkd.in/esiejXq3

Recently, we launched our redesigned website and refreshed brand, showcasing not just a new look, but a renewed commitment to driving success in drug development and commercialization, and improving patient outcomes. ✍️ In our latest blog, Sofie Vandevyver, PhD, Vice President and Global Head of Marketing at Cytel, explains the reasons behind our transformation and the core elements of our new brand. And that's not all! 💡Sofie dives into the hottest industry trends and reveals how we are uniquely positioned to help you unlock the full potential of therapies. Read the full article: https://bit.ly/4cxJIaE #DataScience #DrugDevelopment #NewCytel #Transformation #PatientOutcomes